TG Therapeutics (TGTX) Misses Q3 EPS by 5c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Buildings collapse as quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
TG Therapeutics (TGTX) PT Raised to $36 at SunTrust Robinson Humphrey; Catalyst Rich 6-18 Months
November 9, 2017 7:47 AM ESTSunTrust Robinson Humphrey raised its price target on TG Therapeutics (NASDAQ: TGTX) to $36.00 (from $28.00) while maintaining a Buy rating.
Analyst Suneja Yatin sees the next 6-18 months are a catalyst-rich period for TGTX, with multiple N-T inflection points: (1) UNITY-CLL pivotal ORR... More
